MB5029 / Mustbio - LARVOL DELTA

MB5029: A novel anti-PD-1 x IL-2v with improved safety profile and enhanced anti-tumor efficacy by selectively targeting activated T cells (AACR 2024) - "MB5029 is shown to be well-tolerated up to 9 mg/kg without severe clinical signs and no significant increase in eosinophil and cytokines in the blood. Overall, MB5029 represents a promising potential as an immunotherapeutic approach, as it has demonstrated both strong efficacy and good tolerability, along with improved safety margins."

Clinical • Oncology • CD8 • STAT5

MB5029, a highly TME selective αPD-1/IL-2v bispecific fusion protein modulated to abolish IL-2Rα and attenuate IL-2Rγ binding, shows strong anti-tumor efficacy and good tolerability (SITC 2024) - "mMB5029 is well tolerated at doses up to 60 mg/kg in normal mice with no significant cytokine increase in PB.In cynomolgus monkeys, MB5029 exhibited dose-proportional pharmacokinetic properties, accompanied by lymphocyte expansion in the peripheral blood, and was well-tolerated at doses up to 9 mg/kg without significant cytokine increase or severe adverse effects. Conclusions While αPD-1/IL-2nα bispecific fusion protein shows activation and expansion of CD8 T cells in both PB and TME, MB5029 demonstrates selective activation and expansion of CD8 T cells in the TME while having minimal effect in PB, leading to potent anti-tumor effects and reduced systemic toxicity."

Clinical • Oncology • CD8 • PD-1 • STAT5